Patterns of Colorectal Cancer Care in the United States: 1990-2010

Caitlin C. Murphy, Linda C. Harlan, Jennifer L. Lund, Charles F. Lynch, Ann M. Geiger

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. Methods: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. Results: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 (stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancer patients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; >80 years: RR = 0.37, 95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5% to 66.1%. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95% CI = 0.47 to 0.74; >80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancer patients. Conclusion: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.

Original languageEnglish (US)
Article numberdjv198
JournalJournal of the National Cancer Institute
Volume107
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Colorectal Neoplasms
Rectal Neoplasms
Colonic Neoplasms
Drug Therapy
Radiotherapy
Comorbidity
Therapeutics
Population Surveillance
SEER Program
Mortality
Medical Records
Physicians

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Patterns of Colorectal Cancer Care in the United States : 1990-2010. / Murphy, Caitlin C.; Harlan, Linda C.; Lund, Jennifer L.; Lynch, Charles F.; Geiger, Ann M.

In: Journal of the National Cancer Institute, Vol. 107, No. 10, djv198, 01.10.2015.

Research output: Contribution to journalArticle

Murphy, Caitlin C. ; Harlan, Linda C. ; Lund, Jennifer L. ; Lynch, Charles F. ; Geiger, Ann M. / Patterns of Colorectal Cancer Care in the United States : 1990-2010. In: Journal of the National Cancer Institute. 2015 ; Vol. 107, No. 10.
@article{9f9d4e4c723947ca8cb3c337148c169b,
title = "Patterns of Colorectal Cancer Care in the United States: 1990-2010",
abstract = "Background: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. Methods: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. Results: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5{\%}; stage III: 56.3{\%}) to 2005 (stage II: 32.1{\%}; stage III: 72.4{\%}) and declined slightly in 2010 (stage II: 29.3{\%}; stage III: 66.4{\%}). Stage III colon cancer patients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95{\%} confidence interval [CI] = 0.71 to 0.91; >80 years: RR = 0.37, 95{\%} CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95{\%} CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5{\%} to 66.1{\%}. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95{\%} CI = 0.47 to 0.74; >80 years: RR = 0.33, 95{\%} CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancer patients. Conclusion: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.",
author = "Murphy, {Caitlin C.} and Harlan, {Linda C.} and Lund, {Jennifer L.} and Lynch, {Charles F.} and Geiger, {Ann M.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/jnci/djv198",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Patterns of Colorectal Cancer Care in the United States

T2 - 1990-2010

AU - Murphy, Caitlin C.

AU - Harlan, Linda C.

AU - Lund, Jennifer L.

AU - Lynch, Charles F.

AU - Geiger, Ann M.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. Methods: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. Results: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 (stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancer patients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; >80 years: RR = 0.37, 95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5% to 66.1%. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95% CI = 0.47 to 0.74; >80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancer patients. Conclusion: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.

AB - Background: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. Methods: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. Results: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 (stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancer patients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; >80 years: RR = 0.37, 95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5% to 66.1%. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95% CI = 0.47 to 0.74; >80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancer patients. Conclusion: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.

UR - http://www.scopus.com/inward/record.url?scp=84944685600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944685600&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv198

DO - 10.1093/jnci/djv198

M3 - Article

C2 - 26206950

AN - SCOPUS:84944685600

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

M1 - djv198

ER -